REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

BACKGROUND: In a placebo‐controlled, randomized phase 2 trial (ClinicalTrials.gov identifier NCT01900743), regorafenib improved progression‐free survival (PFS) for patients with doxorubicin‐pretreated advanced nonadipocytic sarcoma. A quality‐adjusted time without symptoms of progression or toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry, Vincent, Basson, Laurent, Bogart, Emilie, Mir, Olivier, Blay, Jean‐Yves, Italiano, Antoine, Bertucci, François, Chevreau, Christine, Clisant‐Delaine, Stéphanie, Liegl‐Antzager, Bernadette, Tresch‐Bruneel, Emmanuelle, Wallet, Jennifer, Taieb, Sophie, Decoupigny, Emilie, Le Cesne, Axel, Brodowicz, Thomas, Penel, Nicolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485075/
https://www.ncbi.nlm.nih.gov/pubmed/28295221
http://dx.doi.org/10.1002/cncr.30661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485075/
https://www.ncbi.nlm.nih.gov/pubmed/28295221
http://dx.doi.org/10.1002/cncr.30661

Ejemplares similares